Lu S, Zhou Q, Liu X, Du Y, et al. Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer. Clin Lung Cancer 2024 Apr 30:S1525-7304(24)00079.
PMID: 38879393